558
Views
11
CrossRef citations to date
0
Altmetric
Oncology

Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged ≥65 years: a retrospective evaluation using Medicare claims

ORCID Icon, , ORCID Icon, , ORCID Icon, & ORCID Icon show all
Pages 1705-1711 | Received 11 May 2018, Accepted 28 Jun 2018, Published online: 25 Jul 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

John Edelsberg, Derek Weycker, Mark Bensink, Charles Bowers & Gary H. Lyman. (2020) Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years. Current Medical Research and Opinion 36:3, pages 483-495.
Read now

Articles from other publishers (10)

Kwonoh Park, Young-Kyung Jeon, Jung Hoon Kim, Younak Choi, Jae-Joon Kim, Sang-Bo Oh, So Yeon Oh, Yun Jeong Hong, Seok Jae Huh, Ilhwan Kim & Seong Hoon Shin. (2023) Comparison of prophylactic effects for chemotherapy induced neutropenia between same-day versus next-day administration of pegteograstim (Neurapeg®) in patients treated with chemotherapy regimen composed of day 1 intensive myleosuppressive agent: A randomized phase III clinical trial. Medicine 102:20, pages e33638.
Crossref
Robert M. Rifkin, Jeffrey Crawford, Reshma L. Mahtani, David C. Dale, Mohit Narang, William W. MacLaughlin, Chanh Huynh, Prasad L. Gawade, Sandra Lewis, Lucy DeCosta, Tatiana Lawrence & Rajesh Belani. (2022) A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices. Supportive Care in Cancer 30:10, pages 7913-7922.
Crossref
Yuki Endo, Takeshi Ishikawa, Kaname Oka, Tomoki Sakakida, Shinya Matsumura, Katsura Mizushima, Toshifumi Doi, Tetsuya Okayama, Kazuhiro Katada, Kazuhiro Kamada, Kazuhiko Uchiyama, Tomohisa Takagi, Hitoshi Fujiwara, Hideyuki Konishi, Yuji Naito & Yoshito Itoh. (2022) Effect of concomitant use of G-CSF and myelosuppressive chemotherapy on bone marrow and peripheral granulocytes in a mouse model. Medical Oncology 39:8.
Crossref
Reshma Mahtani, Jeffrey Crawford, Sinéad M. Flannery, Tatiana Lawrence, Jennifer Schenfeld & Prasad L. Gawade. (2021) Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety. BMC Cancer 21:1.
Crossref
Ali McBride, Neda Alrawashdh, Trace Bartels, Logan Moore, Daniel Persky & Ivo Abraham. (2021) Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy. Future Oncology 17:26, pages 3485-3497.
Crossref
Xiaohua Ma, Jian Kang, Yufang Li & Xiaojian Zhang. (2021) Pegfilgrastim safety and efficacy on the last chemotherapy day versus the next: systematic review and meta-analysis. BMJ Supportive & Palliative Care, pages bmjspcare-2020-002532.
Crossref
Chang Liu, Ying Hao, Lei Wang, Fanlu Meng, Fuyu Wen & Diansheng Zhong. (2021) Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte‐colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study. Thoracic Cancer 12:8, pages 1154-1161.
Crossref
Jeffrey Crawford, Donald C. Moore, Vicki A. Morrison & David Dale. (2021) Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: A review of adherence to present guidelines for usage. Cancer Treatment and Research Communications 29, pages 100466.
Crossref
Amanda J Gerberich, Mark R Attilio & Alison Svoboda. (2020) Revisiting same day administration of pegfilgrastim in the age of biosimilars: A review of literature. Journal of Oncology Pharmacy Practice 26:8, pages 1970-1976.
Crossref
Shuling Li, Jiannong Liu, Charles Bowers, Tamer A. F. S. Garawin, Christopher Kim, Mark E. Bensink & David B. Chandler. (2019) Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma. Supportive Care in Cancer 28:1, pages 113-122.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.